NexgenRx Inc.
NEGXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 19% | 11.1% | 4.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 79.6% | 78.1% | 68.2% | 71.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | $0 | $0 |
| % Margin | 7.3% | -1% | 0.6% | 18.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | -$0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | $0 | -$0 | -$0 | $0 |
| % Margin | 3.7% | -2.4% | -0.2% | 34.1% |
| EPS | 0.006 | -0.005 | -0 | 0.058 |
| % Growth | 227.7% | -1,649% | -100.5% | – |
| EPS Diluted | 0.005 | -0.005 | -0 | 0.054 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | -$0 | -$0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 14.1% | 7.4% | 13.5% | 36.5% |